<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02723942</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-T for GPC3+ HCC</org_study_id>
    <nct_id>NCT02723942</nct_id>
  </id_info>
  <brief_title>CAR-T Cell Immunotherapy for HCC Targeting GPC3</brief_title>
  <official_title>Chimeric Antigen Receptor-Modified T Cell (CAR-T) Immunotherapy for Hepatocellular Carcinoma (HCC) Targeting Glypican-3 (GPC3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to preliminarily evaluate the safety and efficacy of CAR-T cell
      immunotherapy for GPC3 positive hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T
      cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages
      compared with conventional immunotherapy, especially in dealing with patients of hematologic
      malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen
      receptor targeting glypican-3(GPC3) antigen.After CAR-T cell infusion,At periodic intervals,
      the investigators will evaluate clinical symptoms Improved conditions of this disease.Through
      this study,the investigators will evaluate the safety and efficacy of CAR-T cell
      immunotherapy in treating with GPC3 positive malignant glioma patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">August 15, 2017</completion_date>
  <primary_completion_date type="Actual">August 15, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological assessment</measure>
    <time_frame>3 months</time_frame>
    <description>Radiological assessment of the therapeutic effect by systemic or local computed Tomography(CT) or positron emission tomography scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of CAR-T cell immunotherapy (adverse events)</measure>
    <time_frame>4 weeks</time_frame>
    <description>After CAR-T cell infusion,we will observe the potential adverse events related to the T-cell infusion such as high fever,jaundice, kidney failure and so on.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood tumor markers</measure>
    <time_frame>3 months</time_frame>
    <description>tested regularly to reflect the role of the Chimeric Antigen Receptor-Modified T Cell in the removal of residual tumor cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T cell testing</measure>
    <time_frame>3 months</time_frame>
    <description>The level of CAR-T cells will be tested regularly by Real-time Quantitative Polymerase Chain Reaction Detecting System(qPCR) or Flow cytometry to evaluate the proliferation in vivo and long-term survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>GPC3 Positive Hepatocellular Carcinoma</condition>
  <condition>CAR-T Cell Immunotherapy</condition>
  <arm_group>
    <arm_group_label>CAR-T cell immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen by infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T cell immunotherapy</intervention_name>
    <description>This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.</description>
    <arm_group_label>CAR-T cell immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18-70 years.

          2. Gender:both.

          3. GPC3 high expression hepatocellular carcinoma patients.

          4. Non diffuse hepatocellular carcinoma，no extrahepatic metastasis or portal vein
             vascular invasion.

          5. Degree of liver cirrhosis：class A or class B 7 according to Child-puge grading
             standard.

          6. Routine blood test：white blood cell count（WBC)&gt;=3×10^9/L, Lymphocyte percentage&gt;=15%,
             hemoglobinHbo（Hb）&gt;=90g/L, prothrombin time（PT） prolongation&lt;=50% normal value, Cluster
             of differentiation 3(CD3) positive T cell count&gt;=0.8×10^9/L.

          7. Liver and Pancreatic function：Alanine aminotransferase/Aspartate
             transaminase(ALT/AST)&lt;=5 times of the normal value, total bilirubin(TBiL)&lt;=3.0mg/dL,
             albumin(ALB)&gt;=35g/L, prothrombin time(PT):International Normalized Ratio(INR)&lt;=1.7 or
             prothrombin time(PT) prolongation&lt;=4s, Serum lipase&lt;=1.5 times of the normal value,
             Serum amylase&lt;=1.5 times of the normal value.

          8. Renal function：Serum creatinine(SCr)&lt;=221μmol/L(2.5mg/L).

          9. Karnofsky Performance Status(KPS)&gt;=60；Expected survival time&gt;=12 weeks.

         10. Peripheral venous access ；no contraindication of lymphocyte separation.

         11. No other serious complications.

         12. Voluntarily signed informed consent.

        Exclusion Criteria:

          1. Pregnant and lactating women.

          2. Lymphocyte separation or peripheral venous access cannot be performed in patients .

          3. Patients in the active stage of infection or with coagulation disorders.

          4. Patients with a previous history of hepatic coma.

          5. Patients with severe gastrointestinal ulcers or gastrointestinal bleeding.

          6. Patients with organ transplantation or waiting for organ transplantation.

          7. Patients with anticoagulant therapy.

          8. Patients with antiplatelet therapy.

          9. Serum sodium(Na)&lt;125 mmol/L.

         10. Serum potassium(K)&lt;3.5 mmol/L(except patients up to the standards after the use of
             supplements).

         11. Patients with organ failure：

               1. cardiac function：level three or above according to New York Heart Association
                  (NYHA) criteria.

               2. liver function:class C or above according to Child-puge grading standard.

               3. renal function:Chronic kidney disease(CKD) phase 4 or more; renal insufficiency
                  phase Ⅲ or more.

               4. pulmonary function：severe respiratory failure symptoms, involving other organs.

               5. Brain function:central nervous system abnormalities or disturbance of
                  consciousness.

         12. Patients with non controlled infectious diseases,for example,HIV positive, syphilis,
             hepatitis A, hepatitis B, hepatitis C, hepatitis E virus (HEV) positive etc.

         13. Patients used corticosteroids or other immunosuppressive agents in the past 4 weeks.

         14. Patients with autoimmune disease.

         15. Patients with previous history of gene therapy.

         16. The actual transfection rate of T cells was lower than 30% or the proliferation was
             less than 5 times after costimulation.

         17. Patients participated in other drug trials in the past 4 weeks.

         18. Patients received radiation treatment in the past 4 weeks.

         19. Patients do not meet the criteria above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central laboratory in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glypican-3(GPC3)</keyword>
  <keyword>chimeric antigen receptor-modified T cell(CAR-T)</keyword>
  <keyword>hepatocellular carcinoma(HCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

